Alcidion Group Limited · ASX:ALC
Alcidion — FY2021 Earnings Presentation
31 slides from Alcidion's earnings presentation, Sep 15, 2021
Slide 1: FY21 Results Investor Presentation ASX cover announcement
15 September 2021 Australian Securities Exchange 20 Bridge Street, Sydney NSW 2000 For personal use only FY21 Results Investor Presentation Melbourne, Australia – Alcidion Group Limited (ASX: ALC) Managing Director, Kate Quirke, and Chief Financial Officer, Matt Gepp will hold a series of investor p
Slide 2: Investor Presentation FY 2021 Full Year Results
For personal use only Investor Presentation FY 2021 Full Year Results 15 September 2021 1
Slide 3: Helping healthcare organisations harness technology for digitally enabled care
Alcidion helps healthcare organisations harness the power of technology to create a clinically For personal use only relevant environment with digitally enabled care… “Making the right thing to do, the easiest thing to do” 2
Slide 4: Alcidion – a Snapshot
Alcidion – a Snapshot For personal use only • Alcidion has a simple purpose: To transform healthcare with Click Here to Play smart, intuitive technology solutions that improve the efficiency Introductory Video and quality of patient care in healthcare organisations, worldwide • Focus on providing to
Slide 5: Workflow of Patient Information
Workflow of Patient Information For personal use only Seamlessly inter-operating with existing systems or stand alone, Alcidion enables clinicians to make better decisions • ALC products integrate and inter-operate with not only major EMR systems but also “best of breed” applications to create a uni
Slide 6: Product Proposition
Product Proposition For personal use only Challenges Approach Patient Safety • Unlock value in existing IT investments using open standards Real-time critical notifications to clinicians reduce cognitive load with modular approach to minimise clinical risk & prevent poor patient outcomes • Build pre
Slide 7: FY21 Summary
For personal use only FY21 Summary 6
Slide 8: FY21 – Financial Summary
FY21 – Financial Summary For personal use only Strong growth in all key financial metrics and record sold revenue heading into FY22 Revenue $25.9M 39% 1 Recurring Revenue $16.3M 56% 88.3% Improvement $15.1M 2.4pts Gross Sold Revenue For FY22 18% Margin on FY20 (85.9%) $0.5M Underlying EBITDA (Loss)
Slide 9: FY21 – Contracts Summary
FY21 – Contracts Summary For personal use only Milestone contracts across all three geographical regions; focus now on accelerating contract wins • South Tees NHS Hospitals (incl extension): 2nd Miya Precision deployment in UK United • NHSX Clinical Communications Procurement Framework: Smartpage in
Slide 10: FY21 – Corporate Summary
FY21 – Corporate Summary For personal use only Executed key operational and corporate strategies which underpin future growth profile • In April 2021, acquired ExtraMed, a leading UK provider of patient flow management software ExtraMed • 9 NHS Trusts, 6 new for Alcidion; increasing number of NHS Tr
Slide 11: Financial Results
For personal use only Financial Results 10
Slide 12: FY21 – Financial Dashboard
FY21- Financial Dashboard For personal use only Revenue ($M) Revenue By Region FY19 FY20 FY21 H1 $25.9M H2 14.8 $18.6M $16.9M 39% 16% 22% 10% 10.4 44% 9.6 $25.9M $18.6M 56% $16.9M 11.1 7.3 8.2 84% 78% FY19 FY20 FY21 ANZ UK EBITDA ($M) ($0.0M) FY19 FY19 FY20 FY21 ($0.5M) ($3.8M) 11
Slide 13: Profit & Loss
Profit & Loss For personal use only Profit & Loss ($000) FY21 FY20 % Change Key Comments Recurring 16,343 10,458 56% Non-recurring 9,539 8,150 17% • Record FY21 revenue of 25.9M, up 39% on FY20 ($18.6M) Total Revenue 25,882 18,608 39% Cost of Sales (3,018) (2,621) (15%) – Recurring revenue of $16.3M
Slide 14: Summary of Revenue Breakdown
Summary of Revenue Breakdown For personal use only Licence + M&S1 recurring revenue underpin future growth, supported by implementation & service fees benefiting current cash flow Core Offering Products 85%2 Technical Services 15%2 Key Product / Miya Precision, Patientrack, Smartpage Data & analytic
Slide 15: Balance Sheet
Balance Sheet For personal use only Balance Sheet ($000) FY21 FY20 % Change Key Comments Cash & equivalents 25,027 15,948 57% Trade and other receivables 4,114 3,833 7% • Strong balance sheet with $25.0M cash and no debt Other assets - prepayments 1,206 445 171% Current Assets 30,347 20,226 50% – Ra
Slide 16: Cash Flow
Cash Flow For personal use only Cash Flows ($000) FY21 FY20 % Change Key Comments Receipts from customers 32,046 20,543 56% Payments to suppliers & employees (30,510) (22,630) 35% • Record $32.0M receipts from customers, an $11.5M (56%) Interest received 12 74 (84%) increase on FY20 Finance costs (3
Slide 17: Market Position & Operations
For personal use only Market Position & Operations 16
Slide 18: UK - Market Penetration
UK - Market Penetration For personal use only Material revenue increase driven by product module upsell, significant Miya Precision opportunity Alcidion NHS penetration in UK Market Contract Size Upside Potential Large EPR vendors Accessible for Alcidion Total Acute 27 (~19%) 145 Approx. Trusts in U
Slide 19: Acquisition of ExtraMed & Salford Opportunity
Acquisition of ExtraMed & Salford Opportunity For personal use only Long-standing UK market leader in patient flow, addressing key pain-points for hospital staff ExtraMed Overview Salford Opportunity • Leading UK provider with 20+ year track record providing patient • Building the UK’s first ‘Digita
Slide 20: Australia - Market Penetration
Australia - Market Penetration For personal use only Strong relationships incorporating trusted services & product offering provide foundation for expansion Alcidion penetration in AUS Market Growth Focus 1. 1 Established technical services offering holding Health 33 (~44%) 75 relationships with gov
Slide 21: ADF Preferred Party Selection + Other Wins
ADF Preferred Party Selection + Other Wins For personal use only Preferred party to major Australian Defence Force contract Other Key Australian Contracts • Alcidion selected, as part of a Consortium, as preferred provider • Preliminary work completed to support COVID-19 for major healthcare IT proj
Slide 22: Current NZ Market Penetration
Current NZ Market Penetration For personal use only Continuing to hold strong market position whilst progressing Te Manawa Taki pilot project Alcidion penetration in NZ Market Key NZ Contracts & Growth Focus • Te Manawa Taki DHBs: First strategic implementation DHBs 14 (~70%) 20 of Better Meds in So
Slide 23: Miya Precision - 100% cloud deployable platform
Miya Precision - 100% cloud deployable platform For personal use only Miya Precision in the Cloud CASE STUDY • 100% cloud native and deployable • First meeting with South Tees IT team in March 2020 • Full scope of functionality available • Contract signed eight months later in November 2020 • All me
Slide 24: Market Dynamics
For personal use only Market Dynamics 23
Slide 25: UK NHSX – Acceleration of the Digital Strategy
UK NHSX – Acceleration of the Digital Strategy For personal use only Core Pillars of the Digital Strategy (EPR Strategy) • NHSX: joint unit of NHS England and the Department of Health and Social Care, supporting local NHS and care organisations to: Openness Ability to integrate with other platforms
Slide 26: ANZ – Favourable changing landscapes
ANZ – Favourable changing landscapes For personal use only Australia New Zealand Virtual Care & Remote Monitoring Centralising Health Decisions and Spending • Heightened focus (expedited by COVID) on virtual care & remote • NZ Government will consolidate all 20 District Health Boards monitoring driv
Slide 27: Outlook
For personal use only Outlook 26
Slide 28: FY22 – Starting with a strong recurring base
FY22 – Starting with a strong recurring base For personal use only Key Comments • $15.1M of contracted revenue to be recognised in FY22, 18% Contracted Revenue (To be recognised in same year) higher than at similar time last year $26.0m $24.0m • Further $2.9M of scheduled renewal revenue (existing c
Slide 29: Growth Focus in FY22
Growth Focus in FY22 For personal use only Accelerating sales across all regions in line with strategy to become a global leader in healthcare technology 1 All Markets: Upsell Miya Precision (or other modules) to existing Alcidion customers 2 All: Win new Miya Precision installs 3 UK: Listed on Proc
Slide 30: Disclaimer
Disclaimer For personal use only The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidio
Slide 31: For personal use only
For personal use only